
The next generation of obesity treatments is approaching, and physicians already have strong opinions about what will determine their impact.
In a new Sermo survey of 214 active GLP prescribers, physicians expressed considerable optimism about investigational retatrutide. How that clinical promise translates into practice is a more complicated story. As more patients ask for prescription weight-loss medications, physicians are already thinking about who might reach their goals and sustain those results, and whether the patients they’d prescribe retatrutide for could get it through insurance or afford it on their own.
First-line use is already on the table
Nearly three in four physicians (73%) believe retatrutide could have a major impact on obesity treatment or transform the standard of care. That enthusiasm extends to first-line use. If approved, 57% of physicians could envision some form of first-line use, including 39% who would consider it first-line for many appropriate patients.
There’s a meaningful difference between seeing potential in a drug and being willing to consider it at the outset of treatment. The first-line finding suggests physicians are open to revisiting how they use the options they already have as next-generation treatments become available.
Physicians want to see who reaches their goals
More patients reaching their weight-loss goals was the most important factor for 29% of physicians considering a hypothetical choice between retatrutide and tirzepatide (Mounjaro and Zepbound). Another 25% prioritized more durable weight loss. Together, those outcomes were the top consideration for more than half of physicians (53%), compared with 21% who selected greater average weight loss.
The ranking points to a more specific kind of evidence physicians may want as the field grows. Two medications can produce similar average weight loss while differing in how many people reach a particular target. How long patients maintain that result can further distinguish the options.
A physician choosing between treatments may find the most useful evidence in what happened to patients with similar goals and clinical characteristics, particularly if the average results give them little reason to favor either drug.
Rising patient demand is bringing the GLP-3 gray market into focus
Nearly all physicians (96%) report an increase in the past year of patients proactively requesting prescription weight-loss medications, and 76% describe that increase as significant.
The interest extends to treatments still in development. Fifty-six percent of physicians said they’d encountered at least one patient who mentioned using, purchasing, or considering a product marketed as retatrutide outside an authorized clinical trial.
Physicians also expressed concern about what patients might do before approval. Eighty-seven percent reported some level of concern about patients purchasing products marketed as retatrutide before an FDA-approved version is available.
For physicians, the timing matters. By the time there’s a prescribing decision to make about a new medication, some patients may already have expectations about what it could do for them. Those expectations are part of the treatment discussion today, even when the available choices are limited to existing medications.
Access could limit use
Physicians’ interest in first-line use came with a caveat. If retatrutide faced restrictions similar to those affecting today’s obesity medications, 86% said their ability to prescribe it to appropriate patients would be limited, with 58% expecting a moderate or severe limitation. Two-thirds (66%) identified out-of-pocket cost or lack of insurance coverage as the single most likely prescribing barrier, while 17% selected prior authorization requirements.
Those findings put the first-line enthusiasm in perspective. A physician may see a place for retatrutide early in treatment, but the patient’s coverage can determine whether it’s an option at all.
When asked to consider a scenario in which retatrutide was approved as a biologic and lower-cost alternatives took longer to reach the market, 77% of physicians said they would be at least moderately concerned about patients’ ability to access and afford the medication.
The next phase of obesity care could have room for several winners
Looking five years ahead, 38% of physicians expect obesity care to become more personalized, while 22% believe more effective next-generation treatments will largely replace current GLP-1s. As the options expand, physicians may have more reason to choose different medications for patients with the same diagnosis.
For one patient, the choice could turn on which treatment gives them the best chance of reaching a specific weight-loss goal. For another, evidence that the results will last may carry more weight. Cost and coverage can shape either decision. The promise of a wider range of treatments is that physicians can make different recommendations for good clinical reasons, and more patients can find a treatment they can start, afford, and stay on.














